Consequences of Helicobacter pylori cure in ulcer patients

被引:14
作者
Labenz, J [1 ]
机构
[1] Univ Bonn, Dept Internal Med & Gastroenterol, Jung Stilling Hosp, Acad Teaching Hosp, D-57074 Siegen, Germany
关键词
gastro-oesophageal reflux disease; H-pylori; peptic ulcer; bleeding ulcer; ulcer recurrence;
D O I
10.1053/bega.1999.0064
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In the complex pathogenesis of genuine ulcer disease Helicobacter pylori (H. pylori) is an essential, although not on its own sufficient, causal factor. Eradication of the infection heals the active ulcer and, in the long term, leads to a drastic reduction in ulcer recurrence and attendant complications. Some patients remain symptomatic even without ulcer recurrence. and in these, pre-existing, exacerbated or induced gastro-oesophageal reflux disease is probably of some significance. Possible causes of ulcer relapse are reinfection, the use of ulcerogenic drugs and persistent gastric hypersecretion. In adults, and probably also in children from the age of six years, H. pylori reinfection is rare, provided that a sensitive and specific test for H. pylori is carried out at the earliest 4 weeks after concluding anti-bacterial treatment. The most common cause of the reappearance of H. pylori is recrudescence - true reinfection hardly ever occurs. The healing of H. pylori-associated ulcer disease improves the patient's quality of life and possibly also life expectancy. Computer-aided calculations, together with a randomized controlled study, have shown not only that individual patients benefit, but that also the health system profits financially. The hypothetical negative effects of H. pylori eradication treatment are still being controversially discussed.
引用
收藏
页码:133 / 145
页数:13
相关论文
共 89 条
[1]   Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole [J].
Bell, GD ;
Bate, CM ;
Axon, ATR ;
Tildesley, G ;
Martin, JL ;
Taylor, MD ;
Richardson, PDI .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (04) :637-644
[2]   Science, medicine, and the future -: Helicobacter pylori and gastric diseases [J].
Blaser, MJ .
BRITISH MEDICAL JOURNAL, 1998, 316 (7143) :1507-1510
[3]  
BLUM AL, 1990, ULKUSALMANACH 1 PLUS, P11
[4]   Clinical economics review: Helicobacter pylori-associated peptic ulcer disease [J].
Bodger, K ;
Daly, MJ ;
Heatley, RV .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (02) :273-282
[5]  
Boyd EJS, 1996, AM J GASTROENTEROL, V91, P1539
[6]   How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology [J].
Calam, J ;
Gibbons, A ;
Healey, ZV ;
Bliss, P ;
Arebi, N .
GASTROENTEROLOGY, 1997, 113 (06) :S43-S49
[7]  
Calvet X, 1998, AM J GASTROENTEROL, V93, P2501, DOI 10.1111/j.1572-0241.1998.00711.x
[8]   Eradication of H-pylori versus maintenance acid suppression to prevent recurrent ulcer hemorrhage in high risk NSAID users:: A prospective randomized study. [J].
Chan, FKL ;
Sung, JY ;
Suen, R ;
Lee, YT ;
Leung, WK ;
Leung, VKS ;
Wu, JCY ;
Chung, CS .
GASTROENTEROLOGY, 1998, 114 (04) :A87-A87
[9]  
Chow WH, 1998, CANCER RES, V58, P588
[10]   Risk factors for coronary heart disease and infection with Helicobacter pylori:: meta-analysis of 18 studies [J].
Danesh, J ;
Peto, R .
BRITISH MEDICAL JOURNAL, 1998, 316 (7138) :1130-1132